ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
The US Food and Drug Administration has green-lighted two new products designed to stop severe bleeding. Cresilon’s Traumagel received 510(k) clearance, meaning the agency approved it as a new medical device. The product, a plant-based gel that comes in a syringe, is designed to be inserted at the surface of a wound to stop “all types of bleeds,” according to Brooklyn, New York–based Cresilon. Meanwhile, Octapharma’s octaplasLG Powder, a lyophilized form of blood plasma, received an emergency use authorization that specifically allows military personnel to administer it when plasma is unavailable or impractical. The powder is a freeze-dried version of Octapharma’s pooled blood plasma, octaplas, which the FDA approved in 2013.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X